[1]
|
Cao, W., Chen, H.-D., Yu, Y.-W., Li, N. and Chen, W.-Q. (2021) Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020. Chinese Medical Journal, 134, 783-791.
https://doi.org/10.1097/CM9.0000000000001474
|
[2]
|
Arbyn, M., Weiderpass, E., Bruni, L., et al. (2020) Esti-mates of Incidence and Mortality of Cervical Cancer in 2018: A Worldwide Analysis. The Lancet Global Health, 8, e191-e203. https://doi.org/10.1016/S2214-109X(19)30482-6
|
[3]
|
Feng, R.-M., Zong, Y.-N., Cao, S.-M. and Xu, R.-H. (2019) Current Cancer Situation in China: Good or Bad News from the 2018 Global Cancer Statistics? Cancer Communications, 39, 1-12.
https://doi.org/10.1186/s40880-019-0368-6
|
[4]
|
Huang, W. (2017) MicroRNAs: Biomarkers, Diagnostics, and Therapeutics. In: Huang, J., et al., Eds., Bioinformatics in MicroRNA Research. Methods in Molecular Biology, Vol. 1617, Humana Press, New York, 57-67.
https://doi.org/10.1007/978-1-4939-7046-9_4
|
[5]
|
Brown, C.J., Ballabio, A., Rupert, J.L., et al. (1991) A Gene from the Region of the Human X Inactivation Centre Is Expressed Exclusively from the Inactive X Chromosome. Nature, 349, 38-44. https://doi.org/10.1038/349038a0
|
[6]
|
季雪梅. miR-144靶向调节NRAS基因抑制结直肠癌的增殖和迁移的机制研究[D]: [博士学位论文]. 广州: 南方医科大学, 2022. https://doi.org/10.27003/d.cnki.gojyu.2021.000128
|
[7]
|
Beylerli, O., Gareev, I., Sufianov, A., Ilyasova, T. and Guang, Y. (2022) Long Noncoding RNAs as Promising Biomarkers in Cancer. Non-Coding RNA Research, 7, 66-70. https://doi.org/10.1016/j.ncrna.2022.02.004
|
[8]
|
Abozeid, M., Rosato, A. and Sommaggio, R. (2017) Immuno-therapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development. BioMed Re-search International, 2017, Article ID: 5791262.
https://doi.org/10.1155/2017/5791262
|
[9]
|
Bartel, D.P. (2009) MicroRNAs: Target Recognition and Regulatory Functions. Cell, 136, 215-233.
https://doi.org/10.1016/j.cell.2009.01.002
|
[10]
|
贾晶莹, 本巴吉, 韩军, 祁玉娟. miRNA在胃癌诊疗中的研究进展[J]. 医学综述, 2020, 26(17): 3421-3428.
|
[11]
|
殷晓蕾. miR-106a在肿瘤中的研究进展[J]. 生命的化学, 2018, 38(4): 608-614.
https://doi.org/10.13488/j.smhx.20180416
|
[12]
|
Tong, A.W. and Nemunaitis, J. (2008) Modulation of miRNA Ac-tivity in Human Cancer: A New Paradigm for Cancer Gene Therapy? Cancer Gene Therapy, 15, 341-355. https://doi.org/10.1038/cgt.2008.8
|
[13]
|
Kuppers, D.A., Schmitt, T.M., Hwang, H.C., Samraj, L., Clurman, B.E. and Fero, M.L. (2017) The miR-106a~363Xpcl1 miRNA Cluster Induces Murine T Cell Lymphoma Despite Transcrip-tional Activation of the p27Kip1 Cell Cycle Inhibitor. Oncotarget, 8, 50680-50691. https://doi.org/10.18632/oncotarget.16932
|
[14]
|
梁宝云, 杨怡冰, 严雁, 等. 外泌体及其环状RNA在缺血性脑卒中中的研究进展[J]. 中国医药, 2023, 18(7): 1089-1093.
|
[15]
|
Wang, B., Zhang, W., Zhang, G., Kwong, L., Lu, H., Tan, J., Sadek, N., Xiao, M., Zhang, J., Labrie, M., Randell, S., Beroard, A., Sugarman, E., Rebecca, VW., Wei, Z., Lu, Y., Mills, GB., Field, J., Villanueva, J., Xu, X., Herlyn, M. and Guo, W. (2021) Targeting mTOR Signaling Overcomes Acquired Resistance to Combined BRAF and MEK Inhibition in BRAF-Mutant Melanoma. Oncogene, 40, 5590-5599. https://doi.org/10.1038/s41388-021-01911-5
|
[16]
|
张丽静, 孟丽敏, 樊智彬, 等. 大肠癌患者血浆miR-106a的表达及意义[J]. 南方医科大学学报, 2014, 34(3): 354-357.
|
[17]
|
Wang, N., Wang, L., Yang, Y., Gong, L., Xiao, B. and Liu, X. (2017) A Serum Exosomal microRNA Panel as a Potential Biomarker Test for Gastric Cancer. Biochemical and Biophysical Research Communications, 493, 1322-1328.
https://doi.org/10.1016/j.bbrc.2017.10.003
|
[18]
|
和宇峥. miR-106a在结直肠癌中的表达及其生物功能研究[D]: [博士学位论文]. 石家庄: 河北医科大学, 2017.
|
[19]
|
Liang, H., Xu, Y., Chen, M., Zhong, W., Wang, M. and Zhao, J. (2020) Patterns of Response in Metastatic NSCLC during PD-1 or PD-L1 Inhibitor Therapy: Comparison of the RECIST 1.1 and iRECIST Criteria. Thoracic Cancer, 11, 1068-1075. https://doi.org/10.1111/1759-7714.13367
|
[20]
|
Chubachi, S., Yasuda, H., Irie, H., et al. (2016) A Case of Non-Small Cell Lung Cancer with Possible “Disease Flare” on Nivolumab Treatment. Case Reports in Oncological Medicine, 2016, Article ID: 1075641.
https://doi.org/10.1155/2016/1075641
|
[21]
|
许超, 曾劲韬, 黄良祥, 等. 血清外泌体miR-148a联合miR-106a检测用于胃癌筛查的研究探讨[J]. 中国肿瘤临床, 2020, 47(13): 655-660.
|
[22]
|
Tsujiura, M., Ichikawa, D., Komatsu, S., et al. (2010) Circulating microRNAs in Plasma of Patients with Gastric Cancers. British Journal of Cancer, 102, 1174-1179. https://doi.org/10.1038/sj.bjc.6605608
|
[23]
|
Komatsu, S., Ichikawa, D., Tsujiura, M., et al. (2013) Prognostic Impact of Circulating miR-21 in the Plasma of Patients with Gastric Carcinoma. Anticancer Research, 33, 271-276.
|
[24]
|
康博雄, 李海龙, 陈彻, 等. miR-106a-5p在胃癌细胞和胃癌组织中的表达及其调控靶基因信号通路富集分析[J]. 中国普外基础与临床杂志, 2018, 25(8): 923-928.
|
[25]
|
马经伟, 张宁, 朱萌, 等. Has_circ_0045943靶向miR-106a对胃癌细胞生物学特性的影响[J]. 西安交通大学学报(医学版), 2022, 43(4): 509-515.
|
[26]
|
张宁, 蔺刘亚, 李思繁, 朱萌. miR-106a靶向调控TIMP2对人胃癌细胞增殖、转移及EMT的影响[J]. 实用肿瘤学杂志, 2022, 36(2): 105-110.
|
[27]
|
Jobin, P.G., Butler, G.S. and Overall, C.M. (2017) New Intracellular Activities of Matrix Metalloproteinases Shine in the Moonlight. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 1864, 2043-2055.
https://doi.org/10.1016/j.bbamcr.2017.05.013
|
[28]
|
Zhong, C., Cao, M.J, Shu, M., et al. (2019) Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) from Red Seabream (Pagrus major): Molecular Cloning and Biochemical Characterization of Highly Expressed Recombinant Protein. Fish & Shellfish Immunology, 95, 556-563. https://doi.org/10.1016/j.fsi.2019.11.006
|
[29]
|
Wang, X., He, L., Huang, X., et al. (2021) Recent Progress of Exo-somes in Multiple Myeloma: Pathogenesis, Diagnosis, Prognosis and Therapeutic Strategies. Cancers, 13, Article No. 1635. https://doi.org/10.3390/cancers13071635
|
[30]
|
朱萌, 张宁, 陶伟. 外泌体介导miR-106a靶向Smad7调控间皮细胞MMT对胃癌腹膜转移的影响[J]. 临床与实验病理学杂志, 2021, 37(4): 389-393. https://doi.org/10.13315/j.cnki.cjcep.2021.04.003
|
[31]
|
Orimo, A., Gupta, P.B., Sgroi, D.C., et al. (2005) Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion. Cell, 121, 335-348.
https://doi.org/10.1016/j.cell.2005.02.034
|
[32]
|
牟联军. 肌成纤维细胞在食管癌组织中的分布及可能的病理学意义[D]: [硕士学位论文]. 汕头: 汕头大学, 2008.
|
[33]
|
韩嘉熠. 外泌体miR-106a靶向S1PR1促进结直肠癌血管生成并增强血管通透性的研究[D]: [博士学位论文]. 天津: 天津医科大学, 2021. https://doi.org/10.27366/d.cnki.gtyku.2020.000116
|
[34]
|
Loeuillard, E., Yang, J., Buckarma, E., et al. (2020) Tar-geting Tumor-Associated Macrophages and Granulocytic Myeloid-Derived Suppressor Cells Augments PD-1 Blockade in Cholangiocarcinoma. The Journal of Clinical Investigation, 130, 5380-5396. https://doi.org/10.1172/JCI137110
|
[35]
|
Lu, Z., Zou, J., Li, S., et al. (2020) Epigenetic Therapy Inhibits Metastases by Disrupting Premetastatic Niches. Nature, 579, 284-290. https://doi.org/10.1038/s41586-020-2054-x
|
[36]
|
Hangai, S., Kawamura, T., Kimura, Y., et al. (2021) Orchestration of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment by Ubiquitous Cellular Protein TCTP Released by Tumor Cells. Nature Immunology, 22, 947-957.
https://doi.org/10.1038/s41590-021-00967-5
|
[37]
|
任巧利, 李艳超. 肿瘤来源外泌体miR-106a对肝母细胞瘤及其免疫微环境的影响[J]. 实用医学杂志, 2022, 38(19): 2400-2406.
|
[38]
|
张翌, 蔡逊, 金炜东. MiRNA-106a通过作用RUNX3基因诱导胃癌细胞多药耐受[J]. 华中科技大学学报(医学版), 2015, 44(1): 42-46+73.
|
[39]
|
Guo, C., Ding, J., Yao, L., et al. (2005) Tumor Suppressor Gene Runx3 Sensitizes Gastric Cancer Cells to Chemotherapeutic Drugs by Downregulating BCL-2, MDR-1 and MRP-1. International Journal of Cancer, 116, 155-160.
https://doi.org/10.1002/ijc.20919
|
[40]
|
Boortz, H.E., Margolis, D.J.A., Ragavendra, N., et al. (2012) Migration of Intrauterine Devices: Radiologic Findings and Implications for Patient Care. RadioGraphics, 32, 335-352. https://doi.org/10.1148/rg.322115068
|
[41]
|
Liu, J., Huang, Y., Wang, H. and Wu, D. (2018) MiR-106a-5p Pro-motes 5-FU Resistance and the Metastasis of Colorectal Cancer by Targeting TGFβR2. International Journal of Clinical and Experimental Pathology, 11, 5622-5634.
|
[42]
|
Sadek, K.W., Haik, M.Y., Ashour, A.A., et al. (2018) Water-Pipe Smoking Promotes Epithelial-Mesenchymal Transition and Invasion of Human Breast Cancer Cells via ERK1/ERK2 Pathways. Cancer Cell International, 18, Article No. 180. https://doi.org/10.1186/s12935-018-0678-9
|
[43]
|
Ward, R.A., Anderton, M.J., Bethel, P., et al. (2019) Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC). Journal of Medicinal Chemistry, 62, 11004-11018. https://doi.org/10.1021/acs.jmedchem.9b01295
|
[44]
|
Ye, S.-B., Li, Z.-L., Luo, D.-H., et al. (2014) Tumor-Derived Exosomes Promote Tumor Progression and T-Cell Dysfunction Through the Regulation of Enriched Exosomal microRNAs in Human Nasopharyngeal Carcinoma. Oncotarget, 5, 5439-5452. https://doi.org/10.18632/oncotarget.2118
|
[45]
|
刘耿, 李永坤, 刘洪锋. miR-106a-5p靶向ERK2逆转胃癌细胞MGC-803对顺铂化疗的耐药性[J]. 安徽医科大学学报, 2020, 55(5): 722-728. https://doi.org/10.19405/j.cnki.issn1000-1492.2020.05.014
|